2183.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 08:15):

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide...

Stats
Dagens volum	26 600.00
Gjennomsnittsvolum	106 062
Markedsverdi	9.12B
EPS	¥0 ( 2024-02-13 )
Neste inntjeningsdato	( ¥0 ) 2024-05-12
Last Dividend	¥14.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	13.40
ATR14	¥0.611 (0.15%)

Volum Korrelasjon

Lang: -0.32 (neutral)

Kort: -0.06 (neutral)

Signal:(31.363) Neutral

Linical Co., Ltd. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Linical Co., Ltd. Korrelasjon - Valuta/Råvare

0.32
( neutral )

0.64
( weak )

-0.10
( neutral )

0.64
( weak )

-0.30
( neutral )

Linical Co., Ltd. Økonomi

Annual	2022
Omsetning:	¥12.52B
Bruttogevinst:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Omsetning:	¥12.52B
Bruttogevinst:	¥4.16B (33.25 %)
EPS:	¥44.47

FY	2022
Omsetning:	¥11.56B
Bruttogevinst:	¥3.61B (31.26 %)
EPS:	¥35.00

FY	2021
Omsetning:	¥10.28B
Bruttogevinst:	¥2.77B (26.92 %)
EPS:	¥23.91

Financial Reports:

No articles found.

Linical Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥14.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Linical Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.06 - Decrease likely (38.76%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥3.00	2009-03-26
Last Dividend	¥14.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	¥111.75	--
Avg. Dividend % Per Year	0.00%	--
Score	2.77	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.06
Div. Directional Score	7.05	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.77

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9368.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8395.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7818.T	Ex Dividend Knight	2023-08-30	Annually	0.00%
6963.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6317.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
5121.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4249.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3462.T	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
2612.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9948.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0543	1.500	8.91	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0385	1.200	8.72	10.00	[0 - 0.3]
returnOnEquityTTM	0.0876	1.500	-0.138	-0.206	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.712	0.800	6.44	5.15	[1 - 3]
quickRatioTTM	1.467	0.800	6.08	4.86	[0.8 - 2.5]
cashRatioTTM	1.018	1.500	5.46	8.19	[0.2 - 2]
debtRatioTTM	0.154	-1.500	7.43	-10.00	[0 - 0.6]
interestCoverageTTM	71.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.349	-1.500	8.60	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.324	1.000	7.93	7.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0925	1.000	-0.151	-0.151	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.05	9.05	[0.2 - 2]
assetTurnoverTTM	0.708	0.800	8.61	6.89	[0.5 - 2]
Total Score				11.04

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.54	1.000	8.73	0	[1 - 100]
returnOnEquityTTM	0.0876	2.50	-0.0884	-0.206	[0.1 - 1.5]
freeCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	3.68	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	44.92	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.242	1.500	-4.95	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0810	1.000	-0.474	0	[0.1 - 0.5]
Total Score				3.06

Linical Co., Ltd.

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.